Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer
These findings suggest that administration of venetoclax has the potential to enhance suppression of doxorubicin-exposed cancer cells, and that it may have potential as that of Bcl-xL-targeting agents. However, given the variable outcomes in the two triple-negative breast tumor cell lines, it becomes incumbent to identify the factors that confer susceptibility to Bcl- 2 targeting agents in anticipation of their potential utilization in the clinic for combination therapy in solid tumors.
Authors
- Khalid Alhazzani (ORCID: https://orcid.org/0000-0002-1890-1291)
- Eesha Chakraborty (ORCID: https://orcid.org/0000-0003-3957-8064)
- David A. Gewirtz (ORCID: https://orcid.org/0000-0003-0437-4934)
- Hisashi Harada (ORCID: https://orcid.org/0000-0001-5993-1289)
- Mashal M. Almutairi (ORCID: https://orcid.org/0000-0001-9746-4765)
- Moureq Rashed Alotaibi (ORCID: https://orcid.org/0000-0001-7013-6147)
- Tareq Mohammed Saleh (ORCID: https://orcid.org/0000-0002-4088-2410)
- Abdulrahman M. Alanazi (ORCID: https://orcid.org/0000-0003-3663-2627)
- Ali Rashid Alhoshani
- Sultan Almudimeegh
- Faisal Alotaibi
- Basel K. Al-Ramadi
- Homood M. As Sobeai
Institutions
- Hashemite University (JO)
- Virginia Commonwealth University (US)
- United Arab Emirates University (AE)
- King Faisal Specialist Hospital & Research Centre (SA)
- King Fahd Medical City (SA)
- King Saud University (SA)
- Arabian Gulf University (BH)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fcell.2026.1661424
- Primary Topic
- Telomeres, Telomerase, and Senescence
- Type
- article
- Field-Weighted Citation Impact
- 0.00